<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852278</url>
  </required_header>
  <id_info>
    <org_study_id>CReATe 8003</org_study_id>
    <secondary_id>U01TR001263</secondary_id>
    <nct_id>NCT02852278</nct_id>
  </id_info>
  <brief_title>A Patient Centric Motor Neuron Disease Activities of Daily Living Scale</brief_title>
  <official_title>A Patient Centric Motor Neuron Disease Activities of Daily Living Scale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about rates of patient-reported disease progression in
      patients with motor neuron diseases (amyotrophic lateral sclerosis, progressive muscular
      atrophy, primary lateral sclerosis, hereditary spastic paraplegia) outside the clinical
      setting, and the patient-reported clinical characteristics that influence this rate of
      progression. All patients enrolled in CReATe Connect, a Rare Diseases Clinical Research
      Network (RDCRN) Contact Registry, will be invited via email to participate in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient activities of daily living for amyotrophic lateral sclerosis survey (PADL-ALS,
      Appendix B) is a patient-centric revision of the standard revised ALS functional rating scale
      used in clinical trials, the ALSFRS-R. The PADL-ALS was developed based on patient
      interviews, and patient focus groups. The ALSFRS-R is made up of 12 categories detailing
      various activities of daily living and includes six bulbar-respiratory functions, three upper
      extremity functions (writing, cutting food, and dressing), and three gross motor functions
      (walking, climbing, and turning in bed). Each activity is recorded to the closest
      approximation from a list of five choices, scored 0-4, with the total score ranging from 48
      (normal function) to 0 (no function). The PADL-ALS includes questions from the ALSFRS-R, with
      revisions to make the questions easier to understand. In addition the PADL-ALS contains a
      question about pain; a question about emotional lability; and a general non-denominational
      question about faith. The survey will be composed of two parts, the initial survey, and then
      monthly follow up surveys. The initial survey will include the PADL-ALS with additional
      questions about symptom onset, date of diagnosis, initial region involved, patient impression
      of diagnosis, general demographic questions (age, gender, race, ethnicity, education), and
      medications related to their diagnosis of motor neuron disease.

      The survey data will be stored by the Rare Diseases Clinical Research Network's Data
      Management and Coordinating Center (DMCC) at the University of South Florida. Upon conclusion
      of the study period, the data will be sent to Jeffrey Statland, MD, University of Kansas
      Medical Center (Study Chair) and Michael Benatar, MD, PhD, University of Miami (CReATe
      Consortium PI). All data collected will be sent to the database of Genotypes and Phenotypes
      (dbGaP) to be stored indefinitely.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PADL-ALS Survey</measure>
    <time_frame>12 months</time_frame>
    <description>The PADL-ALS survey is a revision of the ALSFR-R, which consists of 12 categories detailing various activities of daily living and includes six bulbar-respiratory functions, three upper extremity functions (writing, cutting food, and dressing) and three gross motor functions (walking, climbing, and turning in bed). Each activity is recorded from a list of five choices, scored 0-4, with the total score ranging from 48 (normal function) to 0 (no function). The PADL-ALS includes questions from the ALSFRS-R, with revisions for easier understanding. The PADL-ALS also includes questions about pain, emotional lability and a general non-denominational question about faith. The survey is composed of an initial survey and monthly follow up surveys. The initial survey will include additional questions about symptom onset, date of diagnosis, initial region involved, patient impression of diagnosis, general demographic questions, and medications related to their diagnosis of motor neuron disease.</description>
  </primary_outcome>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Hereditary Spastic Paraplegia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Web-based Survey</intervention_name>
    <description>This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-reported diagnosis of motor neuron disease (amyotrophic lateral sclerosis,
             amyotrophic lateral sclerosis - frontotemporal dementia, primary lateral sclerosis,
             progressive muscular atrophy, or hereditary spastic paraplegia)

          -  Enrolled in CReATe Connect, an RDCRN Contact Registry

             o Individuals of any age, race, ethnicity, and from any location will be able to
             participate

          -  Participants will need to be able to fill out the survey in English

        Exclusion Criteria:

        â€¢ Inability to provide informed consent and complete survey
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Statland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Benatar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery Krischer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida, Data Management Coordinating Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Callyn Kirk, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <reference>
    <citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review.</citation>
    <PMID>11464847</PMID>
  </reference>
  <reference>
    <citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &quot;Clinical limits of amyotrophic lateral sclerosis&quot; workshop contributors. J Neurol Sci. 1994 Jul;124 Suppl:96-107.</citation>
    <PMID>7807156</PMID>
  </reference>
  <results_reference>
    <citation>Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, Holden D, Norris H. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993 Aug;118(1):48-55.</citation>
    <PMID>8229050</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993 Jan;16(1):27-32.</citation>
    <PMID>8423829</PMID>
  </results_reference>
  <results_reference>
    <citation>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol. 1985;232(5):295-300.</citation>
    <PMID>4056836</PMID>
  </results_reference>
  <results_reference>
    <citation>The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996 Feb;53(2):141-7.</citation>
    <PMID>8639063</PMID>
  </results_reference>
  <results_reference>
    <citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3;330(9):585-91.</citation>
    <PMID>8302340</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller RG, Bouchard JP, Duquette P, Eisen A, Gelinas D, Harati Y, Munsat TL, Powe L, Rothstein J, Salzman P, Sufit RL. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. Neurology. 1996 Oct;47(4 Suppl 2):S86-90; discussion S90-2.</citation>
    <PMID>8858057</PMID>
  </results_reference>
  <results_reference>
    <citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21.</citation>
    <PMID>10540002</PMID>
  </results_reference>
  <results_reference>
    <citation>Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, ChiÃ² A, Corbo M, Giannini F, Inghilleri M, Bella VL, Logroscino G, Lorusso L, Lunetta C, Mazzini L, Messina P, Mora G, Perini M, Quadrelli ML, Silani V, Simone IL, Tremolizzo L; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):397-405. doi: 10.3109/21678421.2013.764568. Epub 2013 Feb 19.</citation>
    <PMID>23421600</PMID>
  </results_reference>
  <results_reference>
    <citation>Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].</citation>
    <PMID>24067398</PMID>
  </results_reference>
  <results_reference>
    <citation>Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):533-6. doi: 10.3109/21678421.2013.823999. Epub 2013 Aug 14.</citation>
    <PMID>23944684</PMID>
  </results_reference>
  <results_reference>
    <citation>Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P, Mantegazza R. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):410-5. doi: 10.3109/17482960902995246.</citation>
    <PMID>19922132</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E; TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007 Aug 21;69(8):776-84.</citation>
    <PMID>17709710</PMID>
  </results_reference>
  <results_reference>
    <citation>Moviglia GA, Moviglia-Brandolino MT, Varela GS, Albanese G, Piccone S, Echegaray G, Martinez G, Blasseti N, Farias J, Farina P, Perusso A, Gaeta CA. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012;21 Suppl 1:S57-63. doi: 10.3727/096368912X633770.</citation>
    <PMID>22507681</PMID>
  </results_reference>
  <results_reference>
    <citation>SaccÃ  F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. J Neurol. 2012 Jan;259(1):132-8. doi: 10.1007/s00415-011-6146-2. Epub 2011 Jun 25.</citation>
    <PMID>21706151</PMID>
  </results_reference>
  <results_reference>
    <citation>Shefner JM, Watson ML, Meng L, Wolff AA; Neals/Cytokinetics STUDY Team. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. doi: 10.3109/21678421.2013.822517. Epub 2013 Aug 19.</citation>
    <PMID>23952636</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, Arbing R, Gordon PH, Mitsumoto H, Levin B, Thompson JL; QALS study group. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007 Feb;8(1):42-6.</citation>
    <PMID>17364435</PMID>
  </results_reference>
  <results_reference>
    <citation>Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, Mitsumoto H. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology. 2006 Oct 10;67(7):1294-6.</citation>
    <PMID>17030772</PMID>
  </results_reference>
  <results_reference>
    <citation>Waitman LR, Aaronson LS, Nadkarni PM, Connolly DW, Campbell JR. The Greater Plains Collaborative: a PCORnet Clinical Research Data Network. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):637-41. doi: 10.1136/amiajnl-2014-002756. Epub 2014 Apr 28.</citation>
    <PMID>24778202</PMID>
  </results_reference>
  <results_reference>
    <citation>Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, Casmiro M, Salvi F, Liguori R, Rizzi R, Pietrini V, Borghi A, Rinaldi R, Fini N, Chierici E, Santangelo M, Granieri E, Mussuto V, De Pasqua S, Georgoulopoulou E, Fasano A; ERRALS Group, Ferro S, D'Alessandro R. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci. 2015 Dec;36(12):2243-52. doi: 10.1007/s10072-015-2343-6. Epub 2015 Jul 24.</citation>
    <PMID>26205535</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Muravov O, Horton K; Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia; Centers for Disease Control and Prevention (CDC). Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Suppl. 2014 Jul 25;63(7):1-14.</citation>
    <PMID>25054277</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomeni R, Fava M; Pooled Resource Open-Access ALS Clinical Trials Consortium. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):119-29. doi: 10.3109/21678421.2013.838970. Epub 2013 Sep 26.</citation>
    <PMID>24070404</PMID>
  </results_reference>
  <results_reference>
    <citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007 Dec;6(12):1045-53. Epub 2007 Nov 5.</citation>
    <PMID>17980667</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>motor neuron diseases</keyword>
  <keyword>Progressive Muscular Atrophy</keyword>
  <keyword>Primary Lateral Sclerosis</keyword>
  <keyword>Hereditary Spastic Paraplegia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

